True North.
The exit machine of Indian mid-market PE: six realisations with numbers in 24 months: Infinity Fincorp at 10x/40% IRR, Niva Bupa's ~₹4,100 Cr monetisation from a ₹510 Cr entry, Zydus/Digvijay/KIMS/Fincare all closed, while Fund VII sits unclosed since 2022.
GW GP Score
True North (née India Value Fund Advisors, 1999) is the oldest control-deal shop in Indian PE and, right now, its cleanest realisation story: the 2024-26 exit ledger reads like a masterclass: build Fincare for 13 years, merge into AU; take Niva Bupa from a ₹510 Cr control entry through IPO and blocks; hand Infinity Fincorp to Partners Group at 10x. The strategic pivot is equally visible: private credit (₹2,000+ Cr raised, 23 deals, second fund launching 50% larger) now out-paces the PE side, and the flagship Fund VII (a GIFT City $650M+₹ sleeve construct) has been raising since 2022 without a announced close. Succession was institutionalised in April 2026 with two co-managing partners.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Fund VII close: raising since 2022; ADB approved Aug 2022.
Niva Bupa residual (~2.9% vs 7.9% conflict: single low-quality source).
Fund VII's four-year raise is the franchise question: exit brilliance hasn't yet converted into flagship-close momentum.
Computed from current dossier sources; analyst override pending.
The realisation benchmark of Indian mid-market PE, graded Stable rather than Positive on one fact: the flagship fund financing all this excellence hasn't closed in four years of trying.
Niva Bupa/Home First monetising; Fund VII book young; Sesa Care scar
Six numbered exits in 24 months incl. a 10x/40% IRR: the desk benchmark
FS/healthcare control depth + credit platform scaling into policy sectors
Credit raising fast; flagship Fund VII unclosed since 2022
27-year founder + formal succession; Singhal reporting confusion noted
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
Niva Bupa liquidity clears with credible OFS/block-sale evidence.
Niva Bupa residual (~2.9% vs 7.9% conflict: single low-quality source).
Fund VII close: raising since 2022; ADB approved Aug 2022.
The exit ledger is the diligence file: six realisations, numbers attached, multiple routes. The question for Fund VII isn't ability but appetite: ask why a 10x-printing franchise needs four years to close, and price the answer.
Fund VII's four-year raise is the franchise question: exit brilliance hasn't yet converted into flagship-close momentum.
Fund VII close: raising since 2022; ADB approved Aug 2022.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 0 pressure catalyst(s); top driver: monthly refresh only.
The funds
~$3bn+ raised across six PE funds + credit platform across 4 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| Fund VII (GIFT) | raising | $650M + ₹150M INR sleeve target | Control mid-market | IFSCA Cat-II; raising since 2022; ADB approved, HDFC AMC in; no announced close (E) |
| Credit platform (Fund I + Opportunities I) | 2022-Correction onset | ₹2,000+ Cr raised | Performing credit | 23 deals, 11 full + 3 partial exits; Fund II launching ~50% larger |
| Fund VI | 2018Expansion | $600M first close (~$900M targeted) | Control | Niva Bupa, Zydus Wellness, Digvijay, Infinity vintage; ADB $50M |
| Funds I-V (IVFA era) | 2000-2015Foundation era | ~$3bn combined | Control | Fincare, Home First, KIMS lineage |
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Latest vehicle is still in market or not publicly closed.
Next liquidityNiva Bupa
4 visible exit events since Jul 2024.
Latest vehicle is still in market or not publicly closed.
5 up / 1 flat / 1 down tracked signals.
No senior departure flagged in key people.
5 up / 1 flat / 1 down
4 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Marked overhangSesa Care: names with negative 12-month mark or momentum signals in the reconstructed book.
Repricing began mid-deployment
Rational growth vintages
Pre-unicorn pricing; discovery-cost entries
Listed Nov 2024; ₹2,700 Cr Bupa sale + IPO OFS + ₹1,082 Cr block; residual ~3-8% (source conflict)
Latest cited source appears to be 2025.
6 visible events tracked.
8 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 4 · +1
Peer median 4 · -3
Peer median 91 · +3
Peer median 66 · -8
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
The latest vehicle is raising, unclosed or stale against the current deployment cycle.
Recent · Latest cited source appears to be 2025.
Niva Bupa residual (~2.9% vs 7.9% conflict: single low-quality source).
Track first/final close, LP quality, target-vs-close delta and mandate shift.
Niva Bupa residual (~2.9% vs 7.9% conflict: single low-quality source).
Niva Bupa: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Team data.
5 total sources · 20% primary
Latest cited source appears to be 2025.
Mergermarket: Infinity Fincorp 10x to Partners Group (2025)
Upgrade Team data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
Control-deal book, deliberately concentrated. 8 tracked below (several mid-exit).
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Niva Bupa | Fintech | 2019 | 51% control (₹510 Cr) | Public | ▲ | Listed Nov 2024; ₹2,700 Cr Bupa sale + IPO OFS + ₹1,082 Cr block; residual ~3-8% (source conflict) |
| Home First | Fintech | 2017 | Control (~$100M) | Public | ▲ | Listed 2021; sell-down continuing: 7.45% → 4.74% Feb 2026 |
| Nivara Home Finance | Fintech | 2025 | Series B led (₹170 Cr of ₹245 Cr) | Private | ▲ | Fund VII's first: affordable housing, ₹700 Cr AUM |
| Embio | Healthcare | 2026 | ~$50M for 25% | Private | · | Fund VII's first pharma: API/CDMO capacity at Dahej |
| Accion Labs | SaaS & Dev Tools | 2022 | Control | Private | → | Tech services |
| Samtel Avionics | Deeptech & Space | 2025 | ₹75 Cr credit + greenshoe | Private | ▲ | Defence electronics: credit platform's policy-sector reach |
| ACN Healthcare | Healthcare | 2026 | ₹150 Cr credit | Private | ▲ | Healthcare RCM at 68% CAGR: Credit Opportunities Fund I |
| Sesa Care | Consumer & Commerce | 2018 | Control | Acquired | ▼ | Merged into Dabur (Oct 2024) at ₹315-325 Cr EV incl. ₹289 Cr debt: the weak outcome on the ledger |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
The cadence tells the strategic story: three credit deals (Oct 2025-Feb 2026) against two PE deals in eighteen months: the credit platform is now the growth engine while Fund VII raises. PE entries stay on-thesis: financial services and healthcare control positions.
Promoter-consolidation financing
Realisation · are LPs getting paid?
Six completed realisations in 24 months, each with published numbers and multiple exit routes: strategic sale (Infinity, KIMS), merger-into-listed (Fincare), staged public-market monetisation (Niva Bupa, Zydus, Home First). The Indian mid-market PE realisation benchmark, with Sesa Care as the honest failure on the same ledger.
Residual 9.54% sold: full exit complete after the India Resurgence Fund control sale (~₹631 Cr agreed 2025).
₹1,950 Cr ($230M) to Partners Group: ~10x MOIC, ~40% IRR (Mergermarket). RBI cleared Oct 2025.
Final 7.27% for ₹879 Cr to PPFAS MF: complete; ~₹1,380 Cr total vs ₹1,000 Cr entry (modest).
7.2% for ₹1,082 Cr at an 11% discount: the monetisation sequence's third leg after the Bupa control sale (₹2,700 Cr) and IPO OFS.
Merged into AU Small Finance Bank (~$530M swap): a 13-year build exited into listed AU stock.
Entire 61% to Blackstone-TPG's Quality Care at ~$400M valuation (closed 2024).
Third-party reported (Mergermarket): the cleanest single print in Indian mid-market PE this cycle
₹4,100+ Cr banked vs ₹510 Cr entry, residual on top
₹2,000+ Cr raised; Fund II launching 50% larger
GIFT structure live and deploying, but the close is four years overdue vs ambition
No fund-level DPI published, but the 2024-26 exit ledger is effectively an audited realisation record. GW read: elite exit execution funding a slow flagship raise: LPs appear to be paying for credit-platform access while watching Fund VII's clock. E.
What they're doing
Control mid-market with a 13-year patience horizon (Fincare) and staged public-market exits (Niva Bupa template).
Private credit as second engine: performing credit + special opportunities, now out-pacing PE deployment.
GIFT City flagship (Fund VII) + INR sleeve: courting domestic LPs alongside ADB-grade institutions.
Succession done deliberately: two internal co-MPs elevated after 20-year apprenticeships.
What can break
Fund VII's four-year raise is the franchise question: exit brilliance hasn't yet converted into flagship-close momentum.
Credit platform growth imports NBFC-style credit risk into a PE house mid-transition.
FS + healthcare concentration (~60% of Fund VI) ties outcomes to two regulated sectors.
Fund VII close: raising since 2022; ADB approved Aug 2022.
Niva Bupa residual (~2.9% vs 7.9% conflict: single low-quality source).
Second credit fund launch (~50% larger corpus, reported Dec 2025).
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
The exit ledger is the diligence file: six realisations, numbers attached, multiple routes. The question for Fund VII isn't ability but appetite: ask why a 10x-printing franchise needs four years to close, and price the answer.
True North's staged-monetisation playbook (control entry → strategic partial → IPO → blocks) is the template for exiting regulated FS assets. Its credit desk also now competes for your portfolio's structured deals.
Watch its credit book as a mid-market stress read: promoter-consolidation financings (Innova/Vee Tee) and defence-electronics lines (Samtel) map where bank credit still doesn't reach.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.